eligibility_summary
Include: adults ≥18 with CD70+ renal/urothelial cancer after failing standard therapy/no options, measurable lesion, ECOG 0–1, life ≥3 mo, adequate organs. Exclude: recent anti‑cancer/immunosuppressive tx, pregnancy/lactation, active HBV/HCV/HIV, unresolved toxicities, prior allo transplant or anti‑CD70 CAR‑T, recent/planned major surgery, active CNS mets, major infection/cardiac/autoimmune disease or immunodeficiency, hypersensitivity to study drugs, other recent malignancy, recent live vaccine.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1 single-arm dose-escalation/expansion trial in CD70-positive advanced urologic cancers. Intervention: Anti-CD70 CAR-T cells (autologous, genetically modified T cells) infused IV after lymphodepletion. Mechanism: CAR recognizes CD70 on tumor cells, CAR signaling (CD3z plus costimulatory domains) activates T cells to expand, secrete cytokines, and kill targets via perforin/granzyme and death-receptor pathways. Conditioning: fludarabine (purine analog antimetabolite) and cyclophosphamide (alkylating agent) deplete lymphocytes to enhance CAR-T engraftment/expansion. Targets/pathways: CD70 expressed on renal and urothelial tumor cells, implicating the CD70-CD27 axis, downstream T-cell activation and cytotoxic effector pathways. Primary aim: determine MTD/RP2D and assess safety/early efficacy.